Loading clinical trials...
Loading clinical trials...
A Single-Arm, Open-Label, Multi-Center, Phase 1b/ 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)
Conditions
Interventions
CTD402 CAR T Cell Injection
Locations
8
United States
Stanford University
Palo Alto, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
University of Chicago
Chicago, Illinois, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York, United States
Start Date
October 7, 2025
Primary Completion Date
September 30, 2028
Completion Date
December 30, 2028
Last Updated
February 5, 2026
NCT06861530
NCT00406757
NCT00199017
Lead Sponsor
BIOHENG THERAPEUTICS US LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions